geboren 1962 in Köln

Ausbildung und Qualifikation

Beruflicher Werdegang

Forschungsschwerpunkt

Forschungsschwerpunkt sind die malignen Lymphome, insbesondere die Planung und Durchführung von klinischen Studien in den Phasen I-III zur Primär- und Rezidivtherapie bei Patienten mit Non-Hodgkin-Lymphomen, Hodgkin und CLL.
Studien und zahlreiche Publikationen zu Prognosefaktoren maligner Lymphome, T-Zell NHL, ZNS Lymphome und LPHD.

Mitgliedschaften

• Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
• Deutsche Studiengruppe Hochmaligne Non-Hodgkin Lymphome (DSHNHL)
• Deutsche CLL-Studiengruppe (DCLLSG)
• Deutsche Studiengruppe Niedrigmaligne Lymphome (GLSG)
• Cochrane Gruppe für Hämato-Onkologische Erkrankungen (CHMG)
• Berufsverband der niedergelassenen Hämatologen und Onkologen Deutschland (BNHO)
• Berufsverband der niedergelassenen Hämatologen und Onkologen Nordrhein (NIONo)

Verzeichnis der wissenschaftlichen Veröffentlichungen

In referierten Journalen publizierte Originalarbeiten

• Awareness and use of psychosocial care among cancer patients and their relatives - a comparison of people with and without a migration background in Germany. S Singer, N Riccetti, I Hempler, M Fried, J Riera Knorrenschild, L Kalie, M Merbach, M Reiser, F Mosthaf, V Heidt, K Hermes‑Moll. J Cancer Res Clin Oncol published 11 June 2022
• Integrated, cross sectoral psycho oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.  M Kusch, H Labouvie, V Schiewer, N Talalaev, JC Cwik, S Bussmann, L Vaganian, AL Gerlach, A Dresen, N Cecon, S Salm, T Krieger, H Pfaff, C Lemmen, L Derendorf, S Stock, C Samel, A Hagemeier, M Hellmich, B Leicher, G Hultenschmidt, J Swoboda, P Haas, A Arning, A Gottel, K Schwickerath, U Graeven, S Houwaart, H Kerek, HC Bodden, S Krebs, C Muth, C Hecker, M Reiser, C Mauch, J Benner, G Schmidt, C Karlowsky, G Vimalanandan, L Matyschik, L Galonska, A Francke, K Osborne, U Nestle, M Baumer, K Schmitz, J Wolf, M Hallek. BMC Health Services Research (2022) 22:543
  
  Cytoreductive treatment in real life: a chart review analysis on 1440
  patients with polycythemia vera. CC Crodel, K Jentsch Ullrich, M Reiser, L Jacobasch, A Sauer, H Tesch, T Ulshöfer, R Wunschel, F Palandri, FH Heidel.
  J Cancer Res Clin Oncol online 22.11.2021
  
  CRISP Registry Group. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M. Lung Cancer. 2021 Feb;152:174-184
  
  Effectiveness and safety of Romiplostim in patients with newly diagnosed, persistent and chronic primary immune-thrombocytopenia in german routine clinical practice: The observational PLATEAU Study. M Reiser, KM Josten, H Dietzfelbinger, A Seesaghur, M Schill, J Hippenmeyer, M Welslau . EHA Library 06/09/21; 324878; EP1157
  
  Clinical Research platform into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315 (A-122).  B Passlick, M Stuschke, A Gröschel, P Christopoulos, M Reck, C Grah, A Groth, A Hipper, M Chiabudini, A Fleitz, M Jänicke, L Spring, D Christoph, C Bernhardt, M Reiser, MO Zahn, M Sebastian, F Griesinger, M Thomas, W Eberhardt. 30. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie 22.-24. September 2021, Erfurt
  
  Welche psychoonkologischen Versorgungserfahrungen und -bedürfnisse haben Krebspatient*innen mit Migrationsgeschichte und deren Angehörige? S Singer, N Riccetti, I Hempler, R Fuchs, M Reiser, M Fried, V Heidt, K Hermes-Moll. 19. Jahrestagung der Arbeitsgemeinschaft für Psychoonkologie (PSO) 23. bis 25. September 2021 - Abstract-ID 88
  
  Discontinuation of tyrosine kinase inhibitor therapy in CML patients outside of clinical trials: Interim results of the German CML VI trial. Kohlbrenner K, Galuschek N, Fabarius A, Reiser M, Fenchel K, Eßeling E, Göhler T, Kühn RB, Depenbusch R, Azeh I, Engel E, Hansen R, Hänel M, Anhuf J, Jehner P, Abu Samra M, Ritter M, Gattermann N, Pelz H, Fuxius S, Oswald B, Baerlocher GM, Brümmendorf TH, Heim D, le Coutre P, Burchert A, Niederwieser D, Tesch H, Hofmann WK, Hochhaus A, Hehlmann R, Saußele S. DGHO 2021 Abstract Poster V157
  
  Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Erste Real-World Evidence zu NSCLC Stadium II und III in Deutschland - AIO-TRK-0315. Eberhardt WEE, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn MO, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group. DGHO 2021 Abstract Poster V288
  
  Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. BMC Cancer. 2020 Feb 24;20(1):155 Westphalen CB, Kukiolka T, Garlipp B, Hahn L, Fuchs M, Malfertheiner P, Reiser M, Kütting F, Heinemann V, Beringer A, Waldschmidt DT.
  
  First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. Martens U, Reiser M, Schirrmacher-Memmel S, Sellmann L, Decker T, Schneeweiss A, Schuler M, Bengsch F, Vannier C, Potthoff K, Marschner N, Kasenda B. DGHO Jahrestagung 2020 Abstract Book
  
  Changes in treatment of patients with multiple myeloma in Germany - results from the MYRIAM registry. Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H. MYRIAM-Studiengruppe  DGHO Jahrestagung 2020 Abstract Book
  
  Influence of the treatment of immune thrombocytopenia (ITP) with Eltrombopag on the fatigue symptoms of ITP patients - Results of the third interim analysis of the German non-interventional study RISA. Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Stauch T, von der Heyde E, Josting A, Plath M, Ballerstädt N, Stark-Lorenzen P, Scheibenbogen C. DGHO Jahrestagung 2020 Abstract Book
  
  Prognosis in patients with advanced pancreatic cancer and effectiveness of 1st-line treatments - a prognostic and comparative effectiveness study using propensity score weighting for patients treated with Gem+Nab vs. FOLFIRINOX from the TPK registry Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach S H, Kreher S, Binninger A, Chiabudini M, Jänicke M, Marschner N. DGHO Jahrestagung 2020 Abstract Book
      
  Interim results of the non-interventional study VALIDATE - 1st-line Panitumumab plus Folfiri or Folfox for patients with RAS wildtype metastastic colorectal cancer in Germany. J Uhlig, J Potenberg, D Semsek, P Stübs, C Fichter, A Köhler, L Müller, M Reiser, HU Siebenbach, T Göhler, L Jacobasch, V Kächele, B Timm, K Potthoff, N Marschner. ESMO Congress September 2020, Posternumber: 457P
  
  Ibrutinib versus Placobo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukomiaa (CLL):Primary endpoint results of the phase 3 double-blind randomized CLL12 TRIAL.  Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. EHA Library. Jun 16, 2019
  
  Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med. 2018 May 15;7(7):2903–12. Dührsen U, Broszeit-Luft S, Dieing A, Lück A, Porowski P, Reiser M, Schwinger U, Klawitter S, Krumm K, Jentsch-Ullrich K.
  
  Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. Eur J Haematol. 2018 Reiser M, Dörfel S, Hensel M, Hoesl M, Jordan WO, Koenigsmann M, Meyer D, Reichert D, Schwarzer A, Marquardt M, Kellershohn K, Jentsch-Ullrich K.
  
  Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C.     
         
  Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyEur J Haematol. 2017 Aug;99(2):169-177. doi: 10.1111/ejh.12900. Epub 2017 Jun 21. Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, Stangel M, Fasshauer M, Gold R, Hensel M.
  
  Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer Case Rep Oncol 2017; 10:627–633Bunck A.C. · Pinto dos Santos D. · Chang D.-H. · Reiser M. · Pfister D. · Bunck A. · Drzezga A. · Maintz D. · Schmidt M.
  
  Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices. Oncol Res Treat. 2017;40(12):784-788. Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R.
  
  Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore. Leuk Lymphoma. 2017 Sep 15:1-4.Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S.
  
  MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
  Clin Cancer Res. 2015 Feb 15;21(4):907-15. doi: 10.1158/1078-0432.CCR-14-0450. Epub 2014 Dec 9. Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G.Epub 2015 Nov 20.
  
  Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17. PMID: 25486127.Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N.
  
  Suboptimal dosing of rituximab in male and female patients with DLBCL.
  Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2.
  Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R
  
  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013 Mar;98(3):364-70. Epub 2012 Dec 14. Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L.
  
  Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsClin Chem Lab Med. 2013 Sep;51(9):1849-57 Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M, Severin K, Schmitz S.
  
  Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol. 2013 Jan;33 Suppl 1: S67-71. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013 Oct 30;5(209):209ra153.Stangel M, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Kirch W, Pittrow D, Reiser M, Gold R.
  
  Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsClin Chem Lab Med. 2013 Sep;51(9):1849-57Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M, Severin K, Schmitz S.
  
  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013 Mar;98(3):364-70. Epub 2012 Dec 14. Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L.
  
  Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsClin Chem Lab Med. 2013 Sep;51(9):1849-57 Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M, Severin K, Schmitz S.
  
  Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol. 2013 Jan;33 Suppl 1: S67-71.Stangel M, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Kirch W, Pittrow D, Reiser M, Gold R.
  
  The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012 Apr 5;119(14):3276-84. Mueller C Mueller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M.
  
  Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012 Nov;25(11):1473-80.Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner R.
  Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80. Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W
  
  Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012 Nov;91(11):1765-72. Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M.
  
  Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Cancer Immunol Immunother. 2012 Oct 23. [Epub ahead of print] Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M.
  
  Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner, R. Mod Pathol. 2012 Nov;25(11):1473-80
     
  Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012 Nov;91(11):1765-72.Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M.
  
  Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia Ann Oncol. 2011 Feb 3.Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M
  
  International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis Ger Med Sci. 2011;9: Doc11. Epub 2011 May 2.Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG;
  
  High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol. 2010 Nov;21(11):2255-61. Epub 2010 May 5. Glass B, Ziepert M, Reiser M, Freund M, Trümper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N
  
  [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods] Med Klin (Munich). 2010 Sep;105(9):647-51. Epub 2010 Sep 28. Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M.:
  
  Strahlenther Onkol. 2009 May;185(5):288-95. Epub 2009 May 15. Eich HT, Heimann M, Stützer H, Kriz J, Reiser M, Müller RP
  
  Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy. Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl
  
  Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin disease J Dtsch Dermatol Ges. 2008 Jan 14Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S
  
  High-dose therapy followed by autologous stem cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma submitted Bertram Glass, Marita Ziepert, Marcel Reiser, Mathias Freund, Lorenz Trümper, Bernd Metzner Alfred Feller, Markus Loeffler, Michael Pfreundschuh, and Norbert Schmitz for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
  
  Six versus Eight Cycles of Bi-weekly CHOP-14 with or without Rituximab for Elderly Patients with Aggressive CD20+ B-Cell Lymphomas Lancet Oncology 2008;9:105-16 Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler
  
  Improvement of Overall Survival in Mantle Cell Lymphoma J Clin Oncol. 2008 Dec 15. [Epub ahead of print] Annina Herrmann, Eva Hoster, Thomas Zwingers, Günter Brittinger, Marianne Engelhardt, Peter Meusers, Marcel Reiser, Roswitha Forstpointner, Bernhard Metzner, Norma Peter, Bernhard Wörmann, Lorenz Trümper, Michael Pfreundschuh, Hermann Einsele, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling
     
  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) Blood. 2008; 111:109-11. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M.
  
  Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone) Ann Hematol. 2008 Sep;87(9):717-26. Epub 2008 Jun 28. Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M
  
  The Addition of Rituximab to Front – Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma – Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) Leukemia. 2008 Sep 25. [Epub ahead of print] Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W
  
  Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008 May;6(5):366-73. Epub 2008 Jan 14.Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S.
  
  Combined Immunochemotherapy With Rituximab Improves Overall Survival in Patients With Indolent Non-Hodgkin lymphoma. Results of a systematic review J Natl Cancer Inst. 2007 May 2;99(9):706-14. Holger Schulz, Julia F. Bohlius, Marcel Reiser, Nicole Skoetz, Sven Trelle, Thilo Kober, Guido Schwarzer, Michael Herold, Martin Dreyling, Michael Hallek and Andreas Engert
  
  Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient Journal of Clinical Virology, Volume 38, Issue 1, Pages 83-86 Sabine Awerkiew, Martin Däumer, Marcel Reiser, Ulrike C. Wend, Herbert Pfister, Rolf Kaiser, Wulf R. Willems, Wolfram H. Gerlich
  
  Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis. Onkologie 2007; 30:564-6Schweighofer CD, Fätkenheuer G, Staib P, Hallek M, Reiser M
  
  A Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert
  
  CHOP improves Response Rates but not Survival and has a lower Hematologic Toxicity as compared to MCP in Follicular and Mantle Cell Lymphomas – Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) Cancer. 2006 Jul 28 Nickenig C., Dreyling M., Hoster E, Pfreundschuh M., Trümper L., Reiser M., Wandt H., Lengfelder E., Ludwig W.-D, Berdel W.E, Metzner B., Forstpointner R., Parwaresch R., Hasford J., Unterhalt M., Hiddemann W.
  
  Prolonged remission in a patient with follicular Lymphoma after a single course of Rituximab. Onkologie. 2006 Mar;29(3):90-2 Jensen M, Elter T, Engert A, Reiser M
  
  U. Töx4, K. Lackner1 Die sonographisch gezielte Implantation von Portkathetersystemen über die laterale Vena subclavia. Fortschr Röntgenstr 2006; 178: 324-329 M. Zähringer, J. Hilgers, K. Krüger, D. Strohe, C. Bangard, L. Neumann, M. Warm, M. Reiser, U.
  
  Prediction of individual response to chemotherapy in patients with acute myeloid leukemia using the chemosensitivity index Ci Br J Haematol. 2005 Mar;128(6):783-91 P. Staib, T. Schinköthe, O.Cornely, M. Reiser, C.Schoch, T. Haferlach, V. Diehl
  
  Fludarabine in Combination with Alemtuzumab (FluCam) is Effective in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial J Clin Oncol. 2005 Oct 1;23(28):7024-31. T. Elter, P. Borchmann, H. Schulz, M. Reiser, M. Jensen, P.Staib, T. Schimköthe, K. Huebel, R. Schnell, A. Josting, A. Engert.
  
  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma - results of a prospective randomized trial of the European MCL network. Blood. 2005 Apr 1;105(7):2677-84 Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.
  
  Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood. 2005 Aug 25 Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M.
  
  Glass Four or six courses of MegaCHOEP (dose-escalated CHOP plus etoposide) and autologous stem cell transplantation in younger patients with high-risk aggressive lymphoma: A randomized study of the German High-Grade Non-Hodgkin Lymphoma Study Group. Cancer. 2005 Dec 5; N. Schmitz, M. Kloess, M. Reiser, W. Berdel, B. Metzner, B. Dörken, M. Kneba, L. Trümper, M. Loeffler, M. Pfreundschuh, B.
  
  A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 acticvates a potent NK activity against myeloma cells in vitro and in vivo. Blood. 2005 Oct 6; [Epub ahead of print] Elke Pogge von Strandmann, Hinrich Hansen, Katrin Reiners, Roland Schnell, Peter Borchmann, Sabine Merkert, Andreas Draube, Marcel Reiser, Ingvill Purr and Andreas Engert
  
  Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long term survival in patients with aggressive malignant Non-Hodgkin Lymphomas - Long term follow-up of a pilot study Leukemia and Lymphoma 2005;46: 1729 – 1734 Susanne Rödel, Andreas Engert, Volker Diehl, and Marcel Reiser
  
  Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital. Onkologie. 2005 Aug;28(8-9):407-11. Trelle S, Staak JO, Jensen M, Engert A, Reiser M.
  
  2-weekly or 3-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good Prognosis (Normal LDH) Aggressive Lymphomas. Results of the NHL-B1 trial of the DSHNHL Blood 2004; 104:626-633 M. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A.C. Feller, C. Rübe, C. Rudolph, M.Reiser, D. Hossfeld, B. Metzner, D.Hasenclever, B. Glass, N. Schmitz, M. Loeffler
  
  German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003 Jun;14(6):881-93. Wunderlich, M. Kloess, M. Reiser, C. Rudolph, L. Truemper, S. Bittner, H. Schmalenberg, R. Schmits, M. Pfreundschuh, M. Loeffler
  
  Rituximab monotherapy is effective in patients with poor risk refractory aggressive non Hodgkin's Lymphoma Haematologica 2004; 89: 857-876 A. Rothe, H. Schulz, T. Elter, A. Engert, M. Reiser
  Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma Cochrane Database Syst Rev. 2004;(3):CD003189 Bohlius J, Reiser M, Schwarzer G, Engert A.
  
  Treatment of relapsed CD20-positive Hodgkin´s lymphoma with the monoclonal antibody rituximab is well tolerated and extremely effective Blood. 2003 Jan 15;101(2):420-4. U. Rehwald, H. Schulz, M. Reiser, V.Diehl, A. Engert.
  
  CHOEP(x5) versus CHOEP(x3) followed by early high dose chemotherapy in primary treatment of aggressive Lymphoma-A randomized phase III study. J Clin Oncol. 2002 Nov 15;20(22):4413-9. A Metzner, D.K. Hossfeld, H.G. Bischoff, A. Franke, M. Reiser
  
  Impact of prophylactic use of granulopoiesis-stimulating factors (G-CSF and GM-CSF) in patients with malignant lymphoma undergoing conventional chemotherapy: A comprehensive meta-analysis. Brit J Haematol 2003; 122, 1-11. J. Bohlius, M. Reiser, A. Engert.
  
  T-cell Non-Hodgkin´s lymphoma: Clinical presentation, histology, treatment outcome and prognostic factors of 66 patients treated at a single institution. Leukemia Lymphoma 2002; 43:805-811 M. Reiser, A. Josting, M. Soltani, P. Staib, B. Salzberger, V. Diehl and A. Engert
  
  Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease Ann Oncol. 2002 Oct;13(10):1628-35. A. Josting, C. Rudolph, M. Reiser, M. Mapara, M. Sieber, H.H. Kirchner, B. Dörken, D.K. Hossfeld, V. Diehl, A. Engert
  
  Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002 Nov 1;100(9):3115-20. H. Schulz, S. K. Klein, U. Rehwald, M. Reiser, A. Hinke, M. Hallek, W E Aulitzky, M. Hensel, M. Herold, D. Huhn, W. Knauf, V. Diehl A. Engert
  
  Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002 May;81(5):258-66 T. Pfitzner, M. Reiser, S. Barth, P. Borchmann, H. Schulz, T. Schinkothe, F. Oberhauser, J. Wessels, M. Tur, V. Diehl, A. Engert.
  
  Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma (Cochrane Review). Cochrane Database Syst Rev. 2002;(4):CD003189. J. Bohlius, M. Reiser, G. Schwarzer, A. Engert
  
  Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Cochrane Database Syst Rev. 2002;(4):CD003189. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A
  
  Primary lymphoma of the conjunctiva -A rare manifestation of indolent non-Hodgkin´s Lymphoma. Ann Hematol 2001: 80:31-313 M. Reiser, A. Josting, V. Diehl and A. Engert U.Kaiser, I. Uebelacker, U. Abel, J. Birkmann, L.Trümper, H. Schmalenberg, T. Karakas,
  
  High platelet contamination in stem cell concentrates results in significant lower CD34+ yield after immunoselection. Transfusion, 2000; 40: 178-181 M. Reiser, A. Draube, C. Scheid, M. Fuchs, A. Josting, V. Diehl and D. Söhngen
  
  Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue - A highly effective regimen for patients with refractory or relapsed indolent lymphoma. Leukemia Lymphoma, 2000; 37: 115-123 A. Josting, M. Reiser, P. Dias Wickramanayake, U. Rueffer, A. Draube, D. Söhngen, H. Tesch, J. Wolf, V. Diehl and A. Engert
  
  Treatment of primary progressive Hodgkin´s and high-grade Non-Hodgkins Lymphoma- Is there a chance for cure? J Clinic Oncol, 2000; 18: 332-339 A. Josting, M. Reiser, B. Salzberger, V. Diehl, A. Engert
  
  Mobilization with etoposide and G-CSF can replace bone marrow harvesting in patients who have previously failed to mobiliz stem cells with cyclophosphamide and G-CSF. J Hematoth Stem cell 2000; 9(4): 411-413 C. Scheid, A. Draube, M. Reiser, A. Josting, M.Fuchs, J. Chemnitz, S. Winter, A. Schulz, A. Engert, V. Diehl, D. Söhngen
  
  
  M. Reiser, B. Salzberger, A. Stiepel, A. Jütte, R. Hoetelmans, G. Fätkenheuer Pharmacokinetics and Virological Efficacy of Nelfinavir plus Saquinavir as Salvage Therapy in HIV-Infected Patients Refractory to Standard Triple Therapy. Eur J Clin Res, 1999; 4: 54-58
  
  Dexa-BEAM is Not Effective in Patients With Relapsed or Resistant Aggressive High-Grade Non-Hodgkin`s Lymphoma. Leukemia Lymphoma, 1999; 33: 305-312 M. Reiser, A. Josting, P. Dias Wickramanayake, A. Draube, C. Scheid, H. Tesch, J. Wolf, V. Diehl and A. Engert.
  
  Two cases of toxoplasmic encephalitis in patients with acute T-cell leukemia and lymphoma. Journal of Infection, 1999; 38: 26-29 D. Re, M. Reiser, S. Bamborschke, R. Schröder, R. Lehrke, H. Tesch, B. Salzberger, V. Diehl, G. Fätkenheuer.
  
  Using at least 5x106 CD34+ cells for autologous transplantation significantly reduces febrile complications and the usage of antibiotics after transplantation. Bone Marrow Transpl 1999; 23: 1177-1181 C. Scheid, A. Draube, M. Reiser, A. Schulz, J. Chemnitz, S. Nelles, M. Fuchs, S. Winter, P.D. Wickramanayake, V. Diehl, D. Söhngen
  
  Successful peripheral blood progenitor cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transpl 1999; 23: 1223-1228 M. Reiser, A. Josting, A. Draube, M.Y. Mapara, C. Scheid, J. Chemnitz, H. Tesch, J. Wolf, V. Diehl, D. Söhngen and A. Engert.
  
  Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV infected patients. AIDS, 1999; 13:1485-1489 G. Fätkenheuer, R. M. W. Hoetelmans, N. Hunn, A. Schwenk, C. Franzen, M. Reiser, A. Jütte, J. Rockstroh, V. Diehl, B. Salzberger
  
  Dexamethasone, Idarubicin, and continuous infusion of Ifosfamide and VP-16 (DIZE) in relapsed and refractory high-grade non-Hodgkin´s lymphoma and Hodgkin´s disease Leukemia Lymphoma 1998, 31: 359-366 M. Reiser, R. Schnell, G. Straub, M. Wilhelm, R. Übelacker, B. Wörmann, B. Winterhalter, R. Münch, V. Diehl and A. Engert.
   
  Raynaud´s Phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi´s sarcoma. Eur J Clin Microb Inf Dis 1998; 17:58-60. M. Reiser, C. Bruns, P. Hartmann, B. Salzberger V. Diehl, G. Fätkenheuer.
  
  A Phase-II Study with idarubicin, ifosfamide and VP-16 (IIVP-16) in Patients with refractory or relapsed agressive and high grade non-Hodgkin´s lymphoma Leukemia Lymphoma 1997; 24: 513-522 A. Engert, R. Schnell, F. Küpper, M. Reiser, M. Engelhard, M. Wilhelm, B. Lathan, S. Baltes-Engeler, B. Winterhalter, M.E. Scheulen, B. Dederichs, H. Tesch, B. Wörmann, and V. Diehl
  
  Paradoxical expansion of intracranial tuberculomas during chemotherapy. Journal of Infection 1997; 35: 88-90. M. Reiser, G. Fätkenheuer, V. Diehl
  
  Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-F116 G. Fätkenheuer, A. Theisen, J. Rockstroh, T. Grabow, C. Wicke, K. Becker, U. Wieland, H. Fister, M. Reiser, P. Hegener, C. Franzen, A. Schwenk und B. Salzberger
  
  Biocompatibility studies of the single-needle technique in plateletpheresis with the Fresenius AS 104 blood cell separator. Beitr Infusionsther 1994; 32: 334-338. R. Moog, J. Kadar, N. Müller, M. Reiser, T. Weisswange, A.E. Ledermann
  
  Vergleichende Evaluierung dreier Leukozytenfilter für Thrombozytenkonzentrate. Beitr. Infusionsther, 1991, Vol 28, 216-219. M. Reiser, J.G. Kadar, H. Borberg

Buchartikel

• M. Reiser, A. Engert, V.Diehl. Time and dose: A crucial factor in high-grade Lymphoma. in ESO scientific Updates, Vol. 3. Dose and timing: The pillars of successful chemotherapy. G. Rosti, editor. 1998 Elsevier Science pp 61-73
• M. Reiser and V. Diehl. New approaches in the medical treatment of malignant Non-Hodgkin´s lymphoma. ESO Educational book XIII advanced Course of Medical Oncology (Madrid 26. Juni-1.Juli 2001)
• M. Reiser, A. Engert. Nodale Non-Hodgkin-Lymphome. In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 5.Auflage 2003 S. 762-766
• M. Reiser und A. Engert. Non-Hodgkin Lymphome. Medizinische Therapie in Klinik und Praxis.Hrsg J. Schölmerich, 1. Auflage 2003. 369 – 371
• M. Reiser, A. Engert. Non-Hodgkin-Lymphome. In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 6.Auflage 2008 S. 139-146
• M. Reiser Chronisch lymphatische Leukämie In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 6.Auflage 2008 S. 155-162

Übersichtsartikel

• M. Reiser, P. Borchmann, V. Diehl, A. Engert. Ifosfamide in the treatment of relapsed lymphoma. Onkologie 1998; 21(Supp. 2:):26-29
• A. Josting, M. Reiser, V. Diehl. Ovarialkarzinom. Medizin im Bild, 1999; 1:22 - 23
• A. Engert, A. Josting, M. Reiser, D. Söhngen,V. Diehl. Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie . Medizinische Klinik 1999; 94:431-442.
• M. Reiser, H. Bredenfeld, A. Engert, V. Diehl. The role of Ifosfamid in the treatment of relapsed and refractory lymphoma. Eur J Haematol 2001: 66 (Suppl.1):36-40.
• M. Reiser, Diehl V. Current treatment of follicular Non-Hodgkin´s lymphoma. E J Cancer 2002;38:1167-1172
• P. Borchmann, M. Reiser Pixantrone Novuspharma Idrugs 2003; 6: 486-490
• Held G., Schubert J, Reiser M, Pfreundschuh M. DOSE-INTENSIFIED TREATMENT OF ADVANCED STAGE DIFFUSE LARGE B-CELL LYMPHOMAS Semin Hematol. 2006 Oct;43(4):221-9.
• P. Borchmann, B. Eichhorst, M. Hellmann, K. Hübel, M. Kochaneck, K. Kreuzer, M. Reiser, M. Hallek. Hämatologie 2008 Dtsch Med Wochenschr 2008; 133:1400-1404